Your browser doesn't support javascript.
loading
Hypofractionated whole breast irradiation in association with hypofractionated or normofractionated boost to the tumor bed in early breast cancer: tolerance and efficacy analysis.
Oses, Gabriela; Barreto, Tanny Daniela; Cases, Carla; Muñoz-Guglielmetti, Diego; Antelo, Gabriela; Mollà, Meritxell.
Afiliação
  • Oses G; Department of Radiation Oncology of Hospital Clinic, Calle Villarroel, 170, 08036, Barcelona, Spain. oses@clinic.cat.
  • Barreto TD; Department of Radiation Oncology of Hospital Clinic, Calle Villarroel, 170, 08036, Barcelona, Spain.
  • Cases C; Department of Radiation Oncology of Hospital Clinic, Calle Villarroel, 170, 08036, Barcelona, Spain.
  • Muñoz-Guglielmetti D; Department of Radiation Oncology of Hospital Clinic, Calle Villarroel, 170, 08036, Barcelona, Spain.
  • Antelo G; Department of Radiation Oncology of Hospital Clinic, Calle Villarroel, 170, 08036, Barcelona, Spain.
  • Mollà M; Department of Radiation Oncology of Hospital Clinic, Calle Villarroel, 170, 08036, Barcelona, Spain.
Clin Transl Oncol ; 25(8): 2419-2426, 2023 Aug.
Article em En | MEDLINE | ID: mdl-36947361
BACKGROUND: The boost to the tumor bed improves local control in breast cancer and it is an important part of the breast conserving therapy. However, information about the use of a hypofractionated boost is sparse, thus further studies are needed. We conducted a retrospective study with the aim of comparing hypofractionated boost (HB) and normofractionated boost (NB) on skin toxicity and local control. MATERIALS AND METHODS: A total of 96 women with early breast cancer undergoing breast-conserving surgery and hypofractionated whole breast irradiation (WBI) were retrospectively analyzed divided into hypofractionated boost group and conventional fractionation boost group. Forty-nine patients were treated with NB with 16 Gy in 8 fractions and 47 patients were treated with HB with 13.35 Gy in 5 fractions. We examined acute and chronic toxicity with CTCAE version 5. RESULTS: The median follow-up was 49.5 months (26-67). Median age was 57 years (36-82). Sixty-six patients (68.7%) were younger than 60 years at the time of boost and 30 (31.2%) were older than 60 years who received the boost due to poor prognostic factors. No differences were found between the two groups in terms of patient, tumor or treatment characteristics. Grade 2 acute skin toxicity was 6.3% in the NB group and 4.2% in the HB group. Chronic skin induration was 4.2% in the NB group and 1% in the HB group. They did not show grade 3 skin toxicity. There were also no differences in acute or late skin toxicity between the two groups. No local recurrences were evidenced. CONCLUSIONS: Hypofractionated WBI associated with HB treatment is a viable option in the management of conservative breast therapy given the good tolerance and similar local control.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Middle aged Idioma: En Revista: Clin Transl Oncol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Espanha País de publicação: Itália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Middle aged Idioma: En Revista: Clin Transl Oncol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Espanha País de publicação: Itália